1. Home
  2. MLTX vs CDNA Comparison

MLTX vs CDNA Comparison

Compare MLTX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoonLake Immunotherapeutics

MLTX

MoonLake Immunotherapeutics

N/A

Current Price

$17.84

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo CareDx Inc.

CDNA

CareDx Inc.

N/A

Current Price

$17.15

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MLTX
CDNA
Founded
2021
1998
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
MLTX
CDNA
Price
$17.84
$17.15
Analyst Decision
Buy
Buy
Analyst Count
10
7
Target Price
$25.70
$27.33
AVG Volume (30 Days)
1.1M
556.0K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$48,324,000.00
Revenue This Year
N/A
$15.37
Revenue Next Year
N/A
$11.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
18.93
52 Week Low
$5.95
$10.96
52 Week High
$62.75
$21.49

Technical Indicators

Market Signals
Indicator
MLTX
CDNA
Relative Strength Index (RSI) 56.37 35.33
Support Level $17.00 $16.74
Resistance Level $19.15 $20.94
Average True Range (ATR) 0.88 0.86
MACD -0.05 -0.20
Stochastic Oscillator 37.35 18.01

Price Performance

Historical Comparison
MLTX
CDNA

About MLTX MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: